Neumora Therapeutics, Inc. (NMRA) Stock Analysis
A live, multi-source view of Neumora Therapeutics, Inc. (NMRA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 63 employees · neumoratx.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Neumora Therapeutics, Inc. (NMRA) had a market capitalization of $246.1M (forward -2.0) and a beta of 2.74; the shares traded in a 52-week range of $0.83 – $3.65 (-21.1% over the year).
- Market cap
- $246.1M
- Enterprise value
- $182.6M
- Forward P/E
- -2.0
- Price / book
- 5.50
- EPS (trailing)
- $-1.23
- EPS (forward)
- $-0.67
- Payout ratio
- 0.0%
- 52-week range
- $0.83 – $3.65
- 52-week change
- -21.1%
- Beta
- 2.74
- Average volume
- 1.9M
- Shares outstanding
- 187.9M
- Short % of float
- 7.27%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Neumora Therapeutics, Inc. (NMRA) last closed at $1.20 (the last completed close before that scan).
Technicals at the scan: RSI 32 (neutral territory), price -18.9% versus its 20-day average, 20-day versus 50-day average spread -5.7%, MACD histogram -0.03.
Sentiment inputs: StockTwits 93% bullish; analyst consensus score 69/100.
Next scheduled company event: in 56 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of NMRA; corporate insiders filed 0 buys and 11 sells (1 filer, latest disclosure 2026-08-21). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Daljit Singh Aurora (0B/11S). Who is trading what
RapidTradeView pick record
NMRA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Neumora Therapeutics, Inc. (NMRA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell NMRA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.